Alan F List
Overview
Explore the profile of Alan F List including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
209
Citations
5735
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Komrokji R, Lanino L, Ball S, Bewersdorf J, Marchetti M, Maggioni G, et al.
Lancet Haematol
. 2024 Oct;
11(11):e862-e872.
PMID: 39393368
The WHO and International Consensus Classification 2022 classifications of myelodysplastic syndromes enhance diagnostic precision and refine decision-making processes in these diseases. However, some discrepancies still exist and potentially cause inconsistency...
2.
Aakash F, Gisriel S, Zeidan A, Bennett J, Bejar R, Bewersdorf J, et al.
Mod Pathol
. 2024 Sep;
37(12):100615.
PMID: 39322118
Myelodysplastic neoplasms/syndromes (MDS) are a heterogeneous group of biologically distinct entities characterized by variable degrees of ineffective hematopoiesis. Recently, 2 classification systems (the 5th edition of the World Health Organization...
3.
Stahl M, Bewersdorf J, Xie Z, Della Porta M, Komrokji R, Xu M, et al.
Blood Rev
. 2023 Sep;
62:101128.
PMID: 37704469
The guidelines for classification, prognostication, and response assessment of myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In this report on behalf of the International Consortium for MDS (icMDS) we...
4.
Bewersdorf J, Xie Z, Bejar R, Borate U, Boultwood J, Brunner A, et al.
Blood Rev
. 2023 Mar;
60:101072.
PMID: 36934059
Biological events that contribute to the pathogenesis of myelodysplastic syndromes/neoplasms (MDS) are becoming increasingly characterized and are being translated into rationally designed therapeutic strategies. Herein, we provide updates from the...
5.
Ward G, Dalton 3rd R, Meyer B, McLemore A, Aldrich A, Lam N, et al.
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36835307
Myelodysplastic Syndromes (MDSs) are bone marrow (BM) failure malignancies characterized by constitutive innate immune activation, including NLRP3 inflammasome driven pyroptotic cell death. We recently reported that the danger-associated molecular pattern...
6.
Mascarenhas J, Gleitz H, Chifotides H, Harrison C, Verstovsek S, Vannucchi A, et al.
Leukemia
. 2022 Nov;
37(2):255-264.
PMID: 36434065
Myelofibrosis (MF) is a myeloproliferative disorder that exhibits considerable biological and clinical heterogeneity. At the two ends of the disease spectrum are the myelodepletive or cytopenic phenotype and the myeloproliferative...
7.
Zeidan A, Bewersdorf J, Buckstein R, Sekeres M, Steensma D, Platzbecker U, et al.
Leukemia
. 2022 Oct;
36(12):2939-2946.
PMID: 36266326
No abstract available.
8.
Stahl M, Abdel-Wahab O, Wei A, Savona M, Xu M, Xie Z, et al.
Blood Adv
. 2022 Oct;
7(12):2709-2714.
PMID: 36260702
No abstract available.
9.
McLemore A, Hou H, Meyer B, Lam N, Ward G, Aldrich A, et al.
JCI Insight
. 2022 Jul;
7(15).
PMID: 35788117
NLRP3 inflammasome and IFN-stimulated gene (ISG) induction are key biological drivers of ineffective hematopoiesis and inflammation in myelodysplastic syndromes (MDSs). Gene mutations involving mRNA splicing and epigenetic regulatory pathways induce...
10.
Shin T, Zhou Y, Chen S, Cordes S, Grice M, Fan X, et al.
Blood
. 2022 Jun;
140(16):1774-1789.
PMID: 35714307
Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking....